ReviewCurrent hematologic malignancy reports2015
Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime?
Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prognostic impact of donor mitochondrial genomic variants in myelodysplastic neoplasms after stem-cell transplantation.Journal of hematology & oncology · 2024Article
- Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation.EClinicalMedicine · 2021Article
- Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT.Blood advances · 2021Article
- Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT.Blood advances · 2019Article
- Genomic prediction of relapse in recipients of allogeneic haematopoietic stem cell transplantation.Leukemia · 2019Article
- Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes.Human mutation · 2018Article
- Article
- Article
- Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex.Blood advances · 2017Article
- Replication of associations between genetic polymorphisms and chronic graft-versus-host disease.Blood · 2016Article
- Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Overall survival following hematopoietic cell transplantation (HCT) has improved over the past two decades through better patient selection and advances in HLA typing, supportive care, and infection prophylaxis. Nonetheless, mortality rates are still unsatisfactory and transplant-related mortality remains a major cause of death after unrelated allogeneic HCT. Since there are no known pre-HCT, non-HLA biologic predictors of survival following transplant, for over a decade, scientists have been investigating the role of non-HLA germline genetic variation in survival and treatment-related mortality after HCT. Variation in single nucleotide polymorphisms (SNPs) has the potential to impact chemotherapy, radiation, and immune responses, leading to different post-HCT survival outcomes. In this paper, we address the current knowledge of the contribution of genetic variation to survival following HCT and discuss study design and methodology for investigating HCT survival on a genomic scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.